Purpose of review: Allergic rhinitis due its high prevalence and burden needs to be properly treated. The disease's clinical features impose well tolerated drugs usable for long-term treatment. Nowadays, second-generation antihistamines and inhaled steroids represent the milestone of rhinitis therapy. The aim of the present review is to provide an update on allergic rhinitis treatment. A particular attention has been deserved to clinical trials, published in the last year that assess the efficacy and safety of new formulation of available drugs or new molecules.
Recent findings: Available and new drugs under investigation seem able to control rhinitis symptoms without a significant patient's burden. The challenge for the next years will be to improve treatment adherence rather than to introduce new drugs.
Summary: Allergic Rhinitis and its Impact on Asthma guidelines have brought attention to allergic rhinitis and its impact on asthma, but have also proposed a new classification in terms of symptoms severity and persistence useful for tailoring treatment on patients’ phenotypes. Their further dissemination is needed; furthermore, they represent a cornerstone for the scientific community through a continuous update on relevant issues such as rhinitis phenotypes, disease management on the basis of new treatments, clinical trials transferability in real life, and allergic rhinitis management in public health programs.
aAllergy and Respiratory Diseases Clinic, DIMI – University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy
bDepartment of Pediatrics, Nippon Medical School, Tokyo, Japan
*Federica Arcadipane and Fiorenza Marugo contributed equally to the writing of this article.
Correspondence to Professor Fulvio Braido, Allergy and Respiratory Diseases Clinic, DIMI – University of Genoa, IRCCS AOU San Martino-IST, Pad. Maragliano, Largo Rosanna Benzi 10, 16132 Genova, Italy. Tel: +390105553524; fax: +390105553524; e-mail: email@example.com